NVO:NYSENovo Nordisk A/S Analysis

Novo Nordisk (NVO) trades at a trailing P/E of 10.1, well below the industry average of 24.1, while delivering a robust 71% ROE and a dividend yield of 4.17%. The stock sits near its technical support at $41, with the current price of $43.19 reflecting a neutral trend (RSI 48.5) and a bearish MACD histogram. Volatility is elevated at ~31% over the past 30 days and beta is 1.42, indicating higher sensitivity to market moves. Recent material news includes FDA approval of oral Wegovy, expanding the obesity franchise, but also a cyber‑extortion incident that raises short‑term regulatory and reputational concerns. Despite a negative free cash flow, operating cash flow remains strong, supporting the dividend payout ratio of 42.6%. The DCF model suggests modest upside (~9% above current levels), reinforcing the view that the stock is fundamentally undervalued.
Overall, the combination of attractive valuation multiples, high profitability, and a growing pipeline positions NVO as a compelling long‑run buy, while short‑term caution is warranted due to technical weakness and cybersecurity risk.